AGMB

6-K - AgomAb Therapeutics NV (0002020932) (Filer)

-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) -- -- Global, randomized, placebo-controlled, dose-ranging study to evaluate three dose levels of ontunisertib, with endoscopic passability at Week 24 as primary endpoint -- -- Study initiation represents an important milestone in the development of ontunisertib as a potential first targeted anti-fibrotic treatment for FSCD -- Antwerp, Belgium, October 13, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that the first patient has been dosed in NOV-ERA

4 - AgomAb Therapeutics NV (0002020932) (Issuer)

-- Open-Label Extension (OLE) Data of STENOVA Phase 2a study with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) selected for oral presentation at UEG Week 2026 -- -- Results support initiation of global NOV-ERA Phase 2b study in FSCD -- -- Agomab-sponsored symposium to discuss the importance of targeting fibro-inflammation in inflammatory bowel disease (IBD) -- Antwerp, Belgium, October 8, 2026 – Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that OLE data of the Phase 2a STENOVA study will be presented in an oral session at United European Gastroenterology (UEG) Week 2026, taking place October 17-20 in B

4 - AgomAb Therapeutics NV (0002020932) (Issuer)

4 - AgomAb Therapeutics NV (0002020932) (Issuer)

4 - AgomAb Therapeutics NV (0002020932) (Issuer)

6-K - AgomAb Therapeutics NV (0002020932) (Filer)

-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period -- -- Radiological assessment shows trend for fibrotic stricture stabilization over treatment course -- -- Sustained disease control observed across symptoms and disease activity scores in Open-Label Extension Study (OLE) -- -- Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming months -- -- Company to host webcast today at 8:30 a.m. Eastern Time --

4 - AgomAb Therapeutics NV (0002020932) (Issuer)

4 - AgomAb Therapeutics NV (0002020932) (Issuer)

3 - AgomAb Therapeutics NV (0002020932) (Issuer)

3 - AgomAb Therapeutics NV (0002020932) (Issuer)

6-K - Agomab Therapeutics NV (0002020932) (Filer)

-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants -- -- Robust target engagement of ALK5 observed with AGMB-447 in IPF patients -- -- Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study before year-end -- Antwerp, Belgium, September 14, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results o

6-K - Agomab Therapeutics NV (0002020932) (Filer)

Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Company's Board of Directors and the proposed consolidation and split adjustment of outstanding pre-Initial Public Offering (IPO) warrants. "We are grateful for the support of our shareholders and ex

Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY.2026 Cantor Global Healthcare Conference. Fireside chat on Friday, September 11, 2026 at 8:00 AM ET in New York, NY.H.C. Wainwright 28th Annual Global Investment Conference. Fireside chat on Tuesday, September 15, 2026 at 2:00 PM ET in New York, NY.Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Wedn

Piper Sandler initiated coverage of AgomAb Therapeutics NV with a rating of Overweight and set a new price target of $60.00

Cantor Fitzgerald initiated coverage of AgomAb Therapeutics NV with a rating of Overweight

6-K - Agomab Therapeutics NV (0002020932) (Filer)

Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026. "We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors," said David Epstein, Chairman of the Board of Agomab. "Marino brings extensive experience building, financing and leading inno

6-K - Agomab Therapeutics NV (0002020932) (Filer)

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic Passability -- -- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b Idiopathic Pulmonary Fibrosis (IPF) Study Cohort with AGMB-447 Expected in Coming Months -- -- On Track to Initiate NOV-ERA Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in with AGMB-447 in IPF in Second Half of 2026 -- -- Cash and Cash Investments at June 30, 2026 of €252 Million, including $208 Million in Gross

B. Riley Securities initiated coverage of AgomAb Therapeutics NV with a rating of Buy and set a new price target of $34.00